A number of research firms have recently issued reports on AERI. downgraded shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. BidaskClub upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, December 11th. HC Wainwright reduced their price target on shares of Aerie Pharmaceuticals from $55.00 to $41.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Oppenheimer reduced their price target on shares of Aerie Pharmaceuticals from $45.00 to $25.00 in a research report on Thursday, November 7th. Finally, Stifel Nicolaus reduced their price target on shares of Aerie Pharmaceuticals from $77.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, November 7th.
Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Aerie Pharmaceuticals by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 4,188,446 shares of the company’s stock worth $123,769,000 after purchasing an additional 79,985 shares during the last quarter. BlackRock Inc. raised its position in shares of Aerie Pharmaceuticals by 11.0% during the 2nd quarter. BlackRock Inc. now owns 3,358,901 shares of the company’s stock worth $99,255,000 after purchasing an additional 331,884 shares during the last quarter. Waddell & Reed Financial Inc. raised its position in shares of Aerie Pharmaceuticals by 14.8% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 1,737,627 shares of the company’s stock worth $51,347,000 after purchasing an additional 224,655 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Aerie Pharmaceuticals during the 3rd quarter worth approximately $27,153,000. Finally, State Street Corp raised its position in shares of Aerie Pharmaceuticals by 12.1% during the 3rd quarter. State Street Corp now owns 1,095,231 shares of the company’s stock worth $21,050,000 after purchasing an additional 118,596 shares during the last quarter.
NASDAQ:AERI traded down $0.11 during mid-day trading on Tuesday, reaching $21.78. The stock had a trading volume of 576,715 shares, compared to its average volume of 796,109. The company has a debt-to-equity ratio of 0.94, a quick ratio of 5.23 and a current ratio of 5.43. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -4.68 and a beta of 0.45. Aerie Pharmaceuticals has a twelve month low of $17.15 and a twelve month high of $50.10. The business has a 50 day simple moving average of $20.30 and a 200 day simple moving average of $23.61.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.02). The firm had revenue of $18.54 million during the quarter, compared to analyst estimates of $17.59 million. Aerie Pharmaceuticals had a negative net margin of 328.34% and a negative return on equity of 77.63%. As a group, sell-side analysts expect that Aerie Pharmaceuticals will post -3.89 earnings per share for the current year.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with .